Skip to Content

Integra LifeSciences Holdings Corp.

Securities Class Action

  • Date:
  • 10/6/2026
  • Company Name:
  • Integra LifeSciences Holdings Corp.
  • Stock Symbol:
  • IART
  • Status:
  • Investigating
  • Filing Date:
  • 9/12/2023

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) on behalf of Integra stockholders. Our investigation concerns whether Integra has violated the federal securities laws and/or engaged in other unlawful business practices.

On October 2, 2026, Integra released its third quarter 2026 financial results, revealing a quarterly revenue of $410 million to $412 million, below consensus estimates of $416.3 million. Additionally, the Company lowered its full-year 2026 revenue guidance to $1.634 billion to $1.654 billion from $1.654 billion to $1.695 billion. The Company attributed its revenue results and guidance cut to “the July flooding event at our Cincinnati facility,” which “caused damage to portions of the facility, equipment, inventory and other assets and resulted in operational disruption to the site.” Integra stated that the “flooding related supply disruption negatively impacted third quarter revenue by approximately $7 million and is expected to negatively impact fourth quarter revenue by approximately $15 million to $20 million.” Additionally, the Company does not expect the Cincinnati facility to “return to full manufacturing operations” until second quarter 2027. During the Company’s second quarter 2026 earnings call, however, Integra CFO Lea Daniels Knight had stated the Company did “not expect the event to have a material impact on our revenue or EPS guidance for 2026.” Following the October 2, 2026 disclosure, the price of Integra shares declined by $3.41 per share, or approximately 21.2%, from $16.09 per share on October 1, 2026 to close at $12.68 on October 2, 2026.

If you are a long-term stockholder of Integra, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out the form below. There is no cost or obligation to you.
Contact Instructions
Please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com with any questions.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Integra LifeSciences Holdings Corp.. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: